Market capitalization | $141.30m |
Enterprise Value | $-7.53m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | -0.26 |
P/S ratio (TTM) P/S ratio | 4.86 |
P/B ratio (TTM) P/B ratio | 1.52 |
Revenue growth (TTM) Revenue growth | 76.24% |
Revenue (TTM) Revenue | $29.07m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Cellectis SA Sponsored ADR forecast:
7 Analysts have issued a Cellectis SA Sponsored ADR forecast:
Sep '24 |
+/-
%
|
||
Revenue | 29 29 |
76%
76%
|
|
Gross Profit | 9.71 9.71 |
36%
36%
|
|
EBITDA | -71 -71 |
4%
4%
|
EBIT (Operating Income) EBIT | -90 -90 |
7%
7%
|
Net Profit | -86 -86 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Head office | France |
CEO | André Choulika |
Employees | 221 |
Founded | 1999 |
Website | www.cellectis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.